CONMED Corporation (FRA:EC8)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.15B -14.3% |
| Revenue (ttm) | 1.19B +4.1% |
| Net Income | 47.57M -53.8% |
| EPS | 1.54 -53.6% |
| Shares Out | n/a |
| PE Ratio | 24.21 |
| Forward PE | 9.78 |
| Dividend | 0.17 (0.45%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | n/a |
| Open | 38.00 |
| Previous Close | 38.00 |
| Day's Range | 38.00 - 38.20 |
| 52-Week Range | 27.60 - 47.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About CONMED
CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems an... [Read more]
Financial Performance
In 2025, CONMED's revenue was $1.37 billion, an increase of 5.18% compared to the previous year's $1.31 billion. Earnings were $47.06 million, a decrease of -64.47%.
Financial numbers in USD Financial StatementsNews
Conmed announces expanded indication for AirSeal Robotic Solution
CONMED (CNMD) Corporation announced that its AirSeal Robotic Solution is now indicated for use with Intuitive’s 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform.
CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that its AirSeal® Robotic Solution is now indicated for use with Intuitive's 8 mm hex cannulas used as part of the Intuiti...
Conmed to present data from randomized controlled clinical trial at SRS meeting
CONMED (CNMD) Corporation announced its participation in the Society of Robotic Surgery 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL. During the meeting, Professor…
CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in For...
Conmed offers could be in $46-$53 per share range, says Needham
Needham keeps a Hold rating on Conmed (CNMD) after Bloomberg reported the company has been exploring a possible sale. A sale makes sense given Conmed’s mid-single digit growth, “strong recurring…
Conmed could be more attractive to financial than strategic buyer, says JPMorgan
JPMorgan notes that Bloomberg reported last Friday that Conmed (CNMD) was considering selling the company after receiving interest from private equity firms. While “hopeful” that Conmed is on an upwar...
Wells finds Conmed sale report ‘little surprising’ after refinance
Wells Fargo keeps an Equal Weight rating on Conmed (CNMD) with a $39 price target after Bloomberg reported the company is exploring a potential sale amid takeover interest from private…
Conmed initiated with a Market Perform at BMO Capital
BMO Capital initiated coverage of Conmed (CNMD) with a Market Perform rating and $36 price target Conmed boasts three compelling and underpenetrated growth platforms in AirSeal, Buffalo Filter, and Bi...
CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The ...
Conmed downgraded to Underperform from Neutral at BofA
BofA analyst Travis Steed downgraded Conmed (CNMD) to Underperform from Neutral with an unchanged price target of $40. When dollars come back into medtech, the firm thinks they will gravitate…
Conmed names John Gallagher as new CFO
CONMED (CNMD) “announced the appointment of John E. Gallagher as Chief Financial Officer, effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory…
CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (“CFO”), effective July 15, 2026. Mr. Gallagher succeeds T...
Conmed appoints Martin, Mirviss to its Board of Directors
Conmed (CNMD) announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors, effective July 1, 2026. Martin will serve as a member of the Audit Committee…
CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin ...
CONMED Transcript: AGM 2026
The meeting confirmed proper notice and quorum, recognized a retiring Board member, and presented three proposals: Director elections, executive compensation, and auditor ratification. All proposals passed by majority vote, with final results to be filed on Form 8-K.
Conmed price target lowered to $40 from $52 at BofA
BofA lowered the firm’s price target on Conmed (CNMD) to $40 from $52 and keeps a Neutral rating on the shares. After having hosted 34 medtech companies last week in…
Conmed price target lowered to $40 from $43 at JPMorgan
JPMorgan lowered the firm’s price target on Conmed (CNMD) to $40 from $43 and keeps a Neutral rating on the shares.
Conmed reports Q1 EPS 89c, consensus 82c
Reports Q1 revenue $317.0M, consensus $310.6M. “Our 2025 momentum continued in the first quarter as we delivered revenue and adjusted earnings ahead of our expectations,” said Patrick J. Beyer, CONMED...
Conmed backs FY26 EPS view of $4.30-$4.45, consensus $4.45
Narrows FY26 revenue view to $1.35B-$1.375B from $1.345B-$1.375B, consensus $1.36B.
CONMED Earnings Call Transcript: Q1 2026
Q1 2026 saw organic sales growth and margin improvement, driven by orthopedics and key platforms, despite a GI product line exit and higher interest expense. Full-year guidance was raised for organic growth, with EPS guidance maintained.
CONMED Earnings release: Q1 2026
CONMED released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
CONMED Slides: Q1 2026
CONMED has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
CONMED Quarterly report: Q1 2026
CONMED has published its Q1 2026 quarterly earnings report on April 29, 2026.
CONMED Corporation Announces First Quarter 2026 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights Sales of $317.0 million decrea...
CONMED Proxy statement: Proxy filing
CONMED filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.